Leap Therapeutics stock (US52195E1029): Q1 2026 results and ticker change to CYPH

Leap Therapeutics reported Q1 2026 financials with a widened net loss but announced a ticker change to CYPH following its rebranding to Cypherpunk Technologies, amid ongoing biotech developments.

Leap Therapeutics, a clinical-stage biopharmaceutical company, released its first quarter 2026 financial results on May 13, 2026, showing a net loss of $19.6 million, wider than prior periods. The company also underwent a significant corporate action with a ticker symbol change from LPTX to CYPH and a name change to Cypherpunk Technologies, as noted in recent corporate action trackers. This comes alongside updates on its pipeline, including Phase 2 LOTUS trial success for abdakibart in Hidradenitis Suppurativa (HS) and a $405 million follow-on offering that extends its cash runway into 2029, according to StockTitan as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Leap Therapeutics
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Oncology, immunology
• Key revenue drivers: Clinical-stage therapies
• Home exchange/listing venue: Nasdaq (LPTX/CYPH)
• Trading currency: USD

Leap Therapeutics: core business model

Leap Therapeutics focuses on developing targeted therapies for cancer and immune diseases, with its lead candidate DKN-01 (now part of its portfolio evolution) targeting the Wnt pathway. The company has shifted emphasis post-acquisitions, including assets from Leap Therapeutics assumed by Avalo via AlmataBio, as detailed in SEC filings. This positions Leap in the competitive biotech space, where innovation in precision medicine drives value for US investors tracking Nasdaq-listed names.

Historically, Leap advanced therapies like galinpepimab for lung cancer, but recent developments highlight pipeline maturation amid financial maneuvers. The recent rebranding to Cypherpunk Technologies signals a strategic pivot, potentially broadening its scope beyond traditional biotech, according to Robinhood as of May 2026.

Main revenue and product drivers for Leap Therapeutics

Leap Therapeutics generates milestone payments and potential royalties from partnered programs, with no commercial products yet. Key drivers include clinical trial progress, such as the Phase 2 LOTUS data success for abdakibart in HS, bolstering its immunology focus. The $405 million raise supports R&D through 2029, critical for biotech firms reliant on funding rounds for US market exposure.

Financials from Q1 2026, published May 13, 2026, reflect R&D expenses tied to these efforts, contributing to the $19.6 million net loss for the quarter ending March 31, 2026.

Industry trends and competitive position

The biotech sector sees robust M&A and financing activity, with Leap's $405M raise exemplifying resilience amid high interest rates. Competitors like Avalo Therapeutics highlight acquisition trends, where Leap's assets integrate into larger pipelines, enhancing competitive positioning in oncology and HS treatments for US healthcare markets.

Why Leap Therapeutics matters for US investors

As a Nasdaq-listed biotech, Leap offers exposure to innovative therapies addressing US-prevalent diseases like cancer and HS. Its extended cash runway reduces dilution risks, appealing to growth-oriented retail investors monitoring clinical milestones and corporate actions like the CYPH ticker change.

Conclusion

Leap Therapeutics' Q1 2026 results highlight ongoing losses offset by clinical wins and substantial financing, alongside a ticker change to CYPH. These developments underscore the dynamic nature of biotech investing, where pipeline progress and capital access are key. US investors should track upcoming trial data and regulatory updates for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.